title: Disability-adjusted life years analysis: implications for stroke research.
abstract: Stroke is a prototype disorder that disables as well as kills people. The disability-adjusted life years (DALY) metric developed by the World Health Organization to measure the global burden of disease integrates healthy life years lost due to both premature mortality and living with disability. Accordingly, it is well suited to stroke research. The DALY has previously been applied only to large but relatively crude population-level data analyses, but now it is possible to calculate the DALY lost in individual stroke patients. Measuring each patient's stroke outcome with DALY lost has expanded its application to the analysis of treatment effect in acute stroke trials, delineating the poststroke complication impact, the differential weighting of discrete vascular events, and estimating a more refined stroke burden in a specific population. The DALY metric has several advantages over conventional stroke outcome measures: 1) Since the DALY measures the burden of diverse health conditions with a common metric of life years lost, stroke burden and benefits of stroke interventions can be directly compared to other health conditions and their treatments. 2) Quantifying stroke burden or interventional benefits as the life years lost or gained makes the DALY metric more intuitively accessible for public and health system planners. 3) As a continuous, equal-interval scale, the DALY analysis might be statistically more powerful than either binary or ordinal rank outcome analyses in detecting the treatment effects of clinical trials. 4) While currently employed stroke outcome measures take one-time snapshots of disability or mortality and implicitly indicate long-term health impact, the DALY explicitly indicates the burdens of living with disability for an individual's remaining life.
authors.affiliation: Department of Neurology, Stroke Center, Ilsan Paik Hospital, Inje University, Goyang, Korea.
authors.forename: Keun-Sik
authors.initials: KS
authors.lastname: Hong
references.citation: Stroke. 2004 May;35(5):1041-6
references.pmid: 15031457
references.citation: Stroke. 2011 Jun;42(6):1722-9
references.pmid: 21527766
references.citation: Stroke. 2003 Jan;34(1):101-4
references.pmid: 12511758
references.citation: Stroke. 2010 Mar;41(3):471-7
references.pmid: 20133917
references.citation: Lancet. 2003 Jul 26;362(9380):271-80
references.pmid: 12892956
references.citation: Circulation. 2009 Jan 27;119(3):480-6
references.pmid: 19171871
references.citation: N Engl J Med. 2010 Jul 1;363(1):11-23
references.pmid: 20505173
references.citation: J Clin Neurol. 2011 Jun;7(2):77-84
references.pmid: 21779295
references.citation: Stroke. 2005 Nov;36(11):2441-5
references.pmid: 16224097
references.citation: Stroke. 2007 Oct;38(10):2633-9
references.pmid: 17702958
references.citation: Arch Intern Med. 2008 Jun 23;168(12):1310-6
references.pmid: 18574088
references.citation: Eur J Neurol. 2008 Dec;15(12):1324-31
references.pmid: 19049549
references.citation: Stroke. 2009 Dec;40(12):3828-33
references.pmid: 19797698
references.citation: Cerebrovasc Dis. 2008;25(5):423-9
references.pmid: 18349536
references.citation: Eur Heart J. 2002 Mar;23(6):458-66
references.pmid: 11863348
references.citation: BMJ. 2008 Feb 16;336(7640):376-9
references.pmid: 18230644
references.citation: Lancet Neurol. 2009 Apr;8(4):345-54
references.pmid: 19233730
references.citation: Stroke. 2005 Sep;36(9):1972-6
references.pmid: 16109909
references.citation: Lancet. 1998 Oct 17;352(9136):1245-51
references.pmid: 9788453
references.citation: Stroke. 2010 Aug;41(8):1758-65
references.pmid: 20595674